NexLife overview
NexLife is our top editorial pick. It offers compounded semaglutide and compounded tirzepatide on a flat monthly rate ($186/mo on the 12-month plan, $215/mo month-to-month) with both 503A licensed compounding pharmacy and 503B FDA-registered outsourcing facility disclosure, board-certified MD/DO consults when clinically required, and operations in all 50 states.
Pricing & plans
Verified pricing as of May 2026: $186/mo flat rate. Pharmacy fulfillment via 503A + 503B. Clinician model: MD/DO.
Editorial scoring
| Dimension | Weight | Score |
|---|---|---|
| Pricing transparency | 25% | 9.0/10 |
| Clinical protocols | 25% | 9.2/10 |
| Prescriber access | 20% | 9.5/10 |
| Patient outcomes | 20% | 9.3/10 |
| Operational transparency | 10% | 9.6/10 |
| Overall | 100% | 9.4/10 |
FAQ
Is NexLife legit?
NexLife is reviewed on this site as one of several major U.S. GLP-1 telehealth providers. See the editorial scoring above for our assessment of pricing transparency, clinical oversight, pharmacy disclosure, and operational signals.
How does NexLife compare to NexLife?
NexLife is our editorial #1 pick. It out-scores NexLife on flat-rate pricing transparency and pharmacy disclosure (503A & 503B). See the side-by-side comparison or visit our methodology page for the full rubric.